Insulet Corporation Class Action Lawsuit – PODD

Key Facts About Insulet Corporation (NASDAQ: PODD)

●       The Allegation: The complaint alleges Insulet publicly touted the safety and quality of its Omnipod insulin delivery products while allegedly concealing that its manufacturing controls and procedures were defective, creating a foreseeable heightened risk that its products would violate safety regulations or pose a risk of injury.

●       The Stock Drop: PODD fell $16.23 per share (6.88%) to close at $219.84 per share on March 13, 2026, after Insulet disclosed a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods tied to a manufacturing issue; PODD then fell $7.79 per share (5.07%) to close at $146.01 per share on May 27, 2026, after Insulet disclosed a second, broader Medical Device Correction affecting approximately 7 million Pods.

●       Class Period & Defendants: The class period runs from February 21, 2025 through May 26, 2026, inclusive. The named defendants are Insulet Corporation and individual defendants Ashley A. McEvoy (President and Chief Executive Officer from April 28, 2025), James R. Hollingshead (President and Chief Executive Officer through April 28, 2025), Flavia H. Pease (Chief Financial Officer from September 30, 2025), Ana M. Chadwick (Chief Financial Officer through September 30, 2025), Eric Benjamin (Chief Operating Officer from August 25, 2025; Chief Product and Customer Experience Officer through August 25, 2025), and Trang Ly (Chief Medical Officer).

●       Lead Plaintiff Deadline: The deadline to apply to serve as lead plaintiff is August 31, 2026. No action is required before the deadline to remain a potential class member. Action before that date is only needed if you wish to seek appointment as lead plaintiff.

Introduction

A securities class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD). The case was brought by shareholder Zhenjun Hu on behalf of investors. It covers a class period from February 21, 2025 through May 26, 2026.

The complaint alleges Insulet made materially false and misleading statements about its manufacturing and product safety. Investors were told the company’s Omnipod products were safe and made at high quality and scale. In reality, plaintiffs claim its manufacturing controls were defective, raising the risk of product safety issues.

The alleged problems surfaced through two voluntary product corrections in 2026. When the news came out, Insulet’s stock dropped sharply on two separate days. Investors who bought shares during the class period say they suffered significant losses.

Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Its products include the Omnipod 5 automated insulin delivery system, which pairs a proprietary algorithm embedded in the pod with a third-party continuous glucose monitor, and the Omnipod Dash, a Bluetooth-enabled pod controlled by a smartphone-like Personal Diabetes Manager. Insulet is headquartered in Acton, Massachusetts, and its common stock trades on NASDAQ under the ticker symbol PODD.

Class Period

February 21, 2025 – May 26, 2026

Investors who purchased or acquired Insulet Corporation (PODD) securities during the Class Period may be eligible to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the class period, Insulet and its senior officers repeatedly assured investors of the safety and quality of the company’s Omnipod insulin delivery products and of Insulet’s ability to manufacture those products at scale. On the February 21, 2025 earnings call that opened the class period, then-CEO James R. Hollingshead told investors the company had spent years building the Omnipod 5 “at scale with quality, high yield, safety and very well protected IP.” The company’s FY 2024 Form 10-K, filed the same day, described its highly automated manufacturing and its Quality team’s work auditing third-party vendors and inspecting and testing products at various steps in the manufacturing cycle.

According to the complaint, similar assurances continued as new executives took the helm. On the August 7, 2025 earnings call, incoming CEO Ashley A. McEvoy stated that Insulet had “pioneered advanced automation in our plants” and built a “robust and secure global supply chain” to deliver its devices “at medical standards.” On the same call, Eric Benjamin stated that the Omnipod 5 “is safe, effective, understood to be really easy to use.” At a September 4, 2025 healthcare conference, McEvoy described the company’s “competitive moats” as including clinical evidence showing safety.

The complaint alleges these representations were materially false and misleading. Plaintiffs claim Insulet’s manufacturing controls and procedures were defective, and that this created a foreseeable heightened risk that one or more Insulet products would be found to violate applicable safety regulations or pose a risk of injury. As a result, according to the complaint, the company’s public statements about product safety and manufacturing quality lacked a reasonable basis at all relevant times.

The complaint further alleges scienter, noting that during the class period the individual defendants sold 21,180 shares of Insulet common stock for over $5.9 million in proceeds. Plaintiffs allege Benjamin sold 12,594 shares for approximately $3.7 million, Hollingshead sold 6,821 shares for approximately $1.8 million, and Chadwick sold 1,765 shares for approximately $441,691.

The Truth Emerges

The complaint alleges the truth began to emerge on March 12, 2026, when Insulet disclosed that it had initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through ongoing product monitoring. The company disclosed that affected Pods might have a small tear in the internal tubing that delivers insulin, which could cause insulin to leak inside the Pod instead of being infused into the body. Insulet characterized the issue as limited, stating that all other Omnipod 5 Pods and Omnipod products remained safe to use, and a company representative later described the correction as affecting only about 1.5% of pods produced in the last year.

According to the complaint, that characterization understated the scope of the problem. On April 29, 2026, the FDA posted that Insulet had reported 476 serious injuries associated with the correction, far more than the 29 confirmed serious adverse events the company had initially cited, though Insulet stated the FDA was referring to 476 Medical Device Reports rather than confirmed serious adverse events. On the May 6, 2026 earnings call, McEvoy continued to emphasize the safety profile of the Omnipod 5 and stated the company had implemented targeted corrective actions to address the manufacturing issue.

The second corrective event came on May 26, 2026, when Insulet disclosed a second voluntary Medical Device Correction, this time covering specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue that could result in insulin under-delivery. Unlike the earlier correction, this one extended to Pod lots distributed in the U.S. and affected international markets and involved approximately 7 million Pods, representing roughly 8.5% of 2025 global Omnipod Pod production. The company disclosed that both corrections related to cannula tears associated with cannula handling at its Acton, Massachusetts facility.

Market Reaction

The disclosures were followed by sharp declines in Insulet’s stock price. After the March 12, 2026 disclosure of the first Medical Device Correction, PODD fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026. After the May 26, 2026 disclosure of the second and broader Medical Device Correction, PODD fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.

Following the second disclosure, analysts lowered their price targets for Insulet’s stock. One firm reduced its price target approximately 9.6%, from $260 to $235, citing continued negative investor sentiment and perceived risk of reputational damage or increased regulatory scrutiny from the second correction. Another wrote that referencing back to the March correction did not sufficiently capture the magnitude of the quality issues and lowered its estimates accordingly.

Next Steps

●       Lead Plaintiff Deadline: August 31, 2026

●       After the lead plaintiff deadline, the Court will consider any lead plaintiff motions.

●       Defendants may file a motion to dismiss.

●       If the case proceeds, the Court may later consider class certification.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Check Eligibility